GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oncology Pharma ONPH · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.04

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Oncology Pharma

Its shares trade under the ticker ONPH. It has been listed since 8 April 1994.

Oncology Pharma, Inc. engages in the development, manufacture and commercialization of therapeutics. The company is headquartered in San Francisco, California. The firm is focused on developing, manufacturing and commercialization of therapeutics. The Company’s portfolio includes Nanosmart Pharmaceuticals and Tulynode. Tulynode is an autologous cellular immune-therapy extracorporeal device. The Company’s NanoSmart's platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Apr 1994
Employees
1

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Oncology Pharma Inc has a strong reputation in the pharmaceutical industry, known for its expertise in oncology treatments.
  • The company has a diverse portfolio of innovative drugs, catering to different types of cancer and targeting specific biological mechanisms.
  • Oncology Pharma Inc has established strategic partnerships with leading research institutions and academic centers, which enhances its access to cutting-edge technologies and clinical trials.

Weaknesses

  • The company has faced challenges in obtaining regulatory approvals for some of its new drugs, creating delays in bringing them to market.
  • Oncology Pharma Inc has a relatively smaller market share compared to some of its larger competitors, limiting its resources and influence in the industry.
  • The company's production capacity may be a constraint, especially if there is high demand for its drugs.

Opportunities

  • The increasing incidence of cancer globally provides Oncology Pharma Inc with a growing market for its oncology drugs.
  • Advancements in personalized medicine and targeted therapies present an opportunity for the company to develop more effective and tailored treatments.
  • Expanding into emerging markets, where there is a rising demand for cancer treatments, can open up new revenue streams for Oncology Pharma Inc.

Threats

  • Competition from larger pharmaceutical companies with greater resources and established market presence pose a threat to Oncology Pharma Inc's market share.
  • Stringent regulatory requirements and increasing scrutiny on pharmaceutical pricing can impact the company's profitability.
  • Changes in healthcare policies and reimbursement systems may affect the market access and affordability of Oncology Pharma Inc's drugs.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.